{"result": "(\"entity\"<|>CT<|>EVENT<|>CT (calcitonin) levels are monitored post-surgery to predict patient outcomes in thyroid cancer cases.)\n##\n(\"entity\"<|>TIROIDECTOMÍA<|>EVENT<|>Tiroidectomía is a surgical procedure recommended for patients with high-risk mutations in MEN2A to prevent thyroid cancer progression.)\n##\n(\"entity\"<|>MEN2A<|>EVENT<|>MEN2A is a genetic condition associated with an increased risk of thyroid cancer, characterized by variable tumor aggressiveness based on specific mutations.)\n##\n(\"entity\"<|>LAURE GIRAUDET<|>PERSON<|>Laure Giraudet is a researcher who conducted a study on the correlation between CT levels and disease progression in thyroid cancer patients.)\n##\n(\"entity\"<|>ALEXANDER EK<|>PERSON<|>Alexander EK is an author of the 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum.)\n##\n(\"entity\"<|>BECK-PECCOZ<|>PERSON<|>Beck-Peccoz is an author of the European Thyroid Association Guidelines for the Diagnosis and Treatment of Thyrotropin-Secreting Pituitary Tumors.)\n##\n(\"entity\"<|>VANDATENIB<|>ORGANIZATION<|>Vandetanib is a tyrosine kinase inhibitor used in systemic therapies for advanced metastatic thyroid cancer.)\n##\n(\"entity\"<|>CABOZANTINIB<|>ORGANIZATION<|>Cabozantinib is a tyrosine kinase inhibitor that has shown benefits in clinical trials for patients with advanced metastatic thyroid cancer.)\n##\n(\"relationship\"<|>LAURE GIRAUDET<|>CT<|>Laure Giraudet's study found a correlation between CT levels and disease progression in thyroid cancer patients<|>8)\n##\n(\"relationship\"<|>MEN2A<|>TIROIDECTOMÍA<|>Tiroidectomía is recommended for patients with MEN2A due to the high risk of thyroid cancer<|>7)\n##\n(\"relationship\"<|>ALEXANDER EK<|>TIROIDECTOMÍA<|>Alexander EK contributed to guidelines that discuss the management of thyroid disease, including the use of tiroidectomía<|>6)\n##\n(\"relationship\"<|>BECK-PECCOZ<|>TIROIDECTOMÍA<|>Beck-Peccoz contributed to guidelines that discuss the management of thyroid disease, including the use of tiroidectomía<|>6)\n##\n(\"relationship\"<|>VANDATENIB<|>CABOZANTINIB<|>Both Vandetanib and Cabozantinib are tyrosine kinase inhibitors used in the treatment of advanced metastatic thyroid cancer<|>7)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: presencia de CT detectable después de la cirugía inicial predice la evolución de\n         cuyo caso se recomienda tiroidectomía profiláctica precoz, durante el primer año, o incluso                                                 estos pacientes, sino que también lo hace la evolución en el tiempo de este parámetro.\n         en los primeros meses de vida.                                                                                                              Un tiempo corto de duplicación de los niveles de CT predice una mala evolución de estos\n         La agresividad de los tumores en el MEN2A es variable según la mutación concreta. La                                                        pacientes. Así, en el estudio de Barbet et al., en los pacientes en los que el tiempo de dupli-\n         mutación más habitual, la del codón 634, es de riesgo alto, por lo que en estos casos se                                                    cación de la CT era inferior a 6 meses, la supervivencia a los 5 y 10 años era de un 25% y\n         recomienda tiroidectomía profiláctica antes de los 5 años.                                                                                  8%, respectivamente; cuando se duplicaba entre 6 meses y 2 años, la supervivencia a los\n                                                                                                                                                     10 años era de un 92%, y si el tiempo de duplicación era superior a 2 años, todos los pacien-\n                                                                                                                                                     tes seguían vivos al final del estudio.\n\n\n\n192                                                                                                                                                                                                                                                                                  193\n---\n                                                                                                                                                                                                                                                         TIROIDES                           3\n\n\n\n               Similares resultados aportan Laure Giraudet et al., en cuyo estudio el 94% de los pacientes                                                 COMENTARIO\n               con un tiempo de duplicación de CT y CEA inferior a 25 meses tenían progresión de su                                                        Esta pregunta plantea básicamente el caso de una mujer de 24 años, embarazada, a quien\n               enfermedad, mientras que el 86% de aquellos cuyo tiempo de duplicación era superior a                                                       se detecta una T4 y una T3 elevadas, con TSH en el límite alto de la normalidad.\n               24 meses tenían enfermedad estable. Por lo tanto, la opción A es cierta.\n               En caso de detectar recurrencia tumoral existe una gran variedad de opciones terapéuticas                                                   Esta situación puede darse tanto en la resistencia a hormonas tiroideas como en los tumo-\n               en función de la localización y accesibilidad de estas, como pueden ser una reintervención                                                  res productores de TSH, por lo que el diagnóstico diferencial debe establecerse fundamen-\n               quirúrgica, radioterapia externa, ablación por radiofrecuencia, quimioembolización, etc. Por                                                talmente      entre estos dos cuadros (opciónes A y C ciertas: respuesta correcta D).\n               consiguiente, la opción B es cierta.                                                                                                        En cuanto a la opción B, es verdad que durante la gestación, especialmente durante el\n               En   cuanto a la posibilidad de utilizar I-131 en estos pacientes, la Guía                          ATA 2015 señala que                     primer trimestre, puede darse un cuadro de hipertiroxinemia debido al efecto estimulante\n               no está indicada. En efecto, en un estudio retrospectivo con 293 pacientes con carcinoma                                                    de la β-HCG sobre el receptor de la TSH. Sin embargo, en esta situación, la TSH endógena de\n               medular de tiroides tiroidectomizados, 61 casos habían recibido una dosis postoperatoria                                                    la paciente     se suprime (opción B falsa).\n               de I-131, mientras que 232 no la recibieron. El periodo libre de enfermedad y la superviven-                                                Referencias:\n               cia fueron similares en los dos grupos. Así pues, la opción C es falsa.                                                                     • Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, et al. 2017 Guidelines of the American Thyroid Association for the\n                                                                                                                                                             Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27:315-89.\n               Finalmente, en caso de enfermedad metastásica progresiva o sintomática se pueden apli-                                                      • Beck-Peccoz P, Lania A, Beckers A, Chatterjee K, Wemeau J.-L. 2013 European Thyroid Association Guidelines for the Diagnosis and\n                                                                                                                                                             Treatment of Thyrotropin-Secreting Pituitary Tumors. Eur Thyroid J. 2013;2:76-82.\n               car terapias sistémicas. De estas, las que mayor evidencia poseen son los inhibidores de la                                                 • Ortiga-Carvalho TM, Sidhaye AR, Wondisford FE. Thyroid hormone receptors and resistance to thyroid hormone disorders. Nat Rev\n               tirosina cinasa. Los inhibidores de la tirosina cinasa autorizados para esta indicación son el                                                Endocrinol. 2014;10:582-91.\n               vandetanib y cabozantinib, de los que existen ensayos clínicos que demuestran                                      beneficios\n               en los pacientes con enfermedad metastásica avanzada. Por lo tanto, la opción D es cierta.                                                  Para el diagnóstico            diferencial, ¿cuál de estas pruebas no aportaría datos\n                                                                                                                                                       57\n               Referencias:                                                                                                                                signific\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}